The oncologist · 2020
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Merryman Reid W, Carreau Nicole A, Advani Ranjana H, Spinner Michael A, Herrera Alex F, Chen Robert, Tomassetti Sarah, Ramchandren Radhakrishnan, Hamid Muhammad, Assouline Sarit, Santiago Raoul, Wagner-Johnston Nina, Paul Suman, Svoboda Jakub, Bair Steven M, Barta Stefan K, Liu Yang, Nathan Sunita, Karmali Reem, Burkart Madelyn, Torka Pallawi, David Kevin A, Wei Catherine, Lansigan Frederick, Emery Lukas, Persky Daniel, Smith Sonali M, Godfrey James, Chavez Julio, Cohen Jonathan B, Troxel Andrea B, Diefenbach Catherine, Armand Philippe
Аннотация
Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treated with ICB; 20 who received TBP (TBP cohort) and 44 who stopped ICB at initial progression (non-TBP cohort). The TBP cohort received ICB for a median of 4.7 months after initial progression and delayed subsequent treatment by a median of 6.6 months. Despite receiving more prior lines of therapy, the TBP cohort achieved longer progression-free survival with post-ICB treatment (median, 17.5 months vs. 6.1 months, p = .035) and longer time-to-subsequent treatment failure, defined as time from initial ICB progression to failure of subsequent treatment (median, 34.6 months vs. 9.9 months, p = .003). With the limitations of a retrospective study, these results support the clinical benefit of TBP with ICB for selected patients.